Press release
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Investor Notice: Investigation of Takeover by AbbVie Inc
An investigation on behalf of investors of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE).
Investors who purchased shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and currently hold any of those NASDAQ: CERE shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Cerevel Therapeutics Holdings, Inc. breached their fiduciary duties owed to NASDAQ: CERE investors in connection with the proposed acquisition.
Cambridge, MA based Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. On December 06, 2023, AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) announced an agreement under which AbbVie will acquire Cerevel Therapeutics. Under the terms of the transaction AbbVie Inc. (NYSE: ABBV) will acquire all outstanding Cerevel Therapeutics (NASDAQ: CERE) common stock for $45.00 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ: CERE stockholders. More specifically, the investigation concerns whether the Cerevel Therapeutics Holdings, Inc. Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Those who are current investors in Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Investor Notice: Investigation of Takeover by AbbVie Inc here
News-ID: 3478027 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Investors in UiPath Inc. (NYSE: PATH) over potential …
An investigation was announced for current long-term investors in shares of UiPath Inc. (NYSE: PATH) concerning potential breaches of fiduciary duties by certain directors and officers of UiPath Inc.
Investors who are current long term investors in UiPath Inc. (NYSE: PATH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Investors who lost money with shares of Equinix, Inc. (NASDAQ: EQIX) should cont …
An investor, who purchased shares of Equinix, Inc. (NASDAQ: EQIX), filed a lawsuit over alleged violations of Federal Securities Laws by Equinix, Inc.
Investors who purchased shares of Equinix, Inc. (NASDAQ: EQIX) have certain options and for certain investors are short and strict deadlines running. Deadline: July 1, 2024. NASDAQ: EQIX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Redwood City, CA based Equinix (Nasdaq: EQIX)…
Investigation announced for Investors in shares of AdaptHealth Corp. (NASDAQ: AH …
An investigation was announced over potential breaches of fiduciary duties by certain directors and officers of AdaptHealth Corp.
Investors who are current long term investors in AdaptHealth Corp. (NASDAQ: AHCO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: AHCO stocks follows a lawsuit filed against AdaptHealth Corp. over alleged…
Lawsuit filed for Investors who lost money with shares of Globe Life Inc. (NYSE: …
An investor, who purchased shares of Globe Life Inc. (NYSE: GL), filed a lawsuit over alleged violations of Federal Securities Laws by Globe Life Inc. f/k/a Torchmark Corporation.
Investors who purchased shares of Globe Life Inc. (NYSE: GL) have certain options and for certain investors are short and strict deadlines running. Deadline: July 1, 2024. NYSE: GL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Cerevel
Schizophrenia Therapeutics Pipeline Assessment | Clinical and Non-Clinical Studi …
DelveInsight assessed more than 70+ companies are working on developing 70+ pipeline therapies in the Schizophrenia Pipeline landscape.
"Schizophrenia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Schizophrenia Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA…
Europe High Throughput Screening Market Growth Sturdy at 8.1% CAGR to Outstrip U …
The Europe high throughput screening market is expected to reach US$ 8,578.43 million in 2028 from US$ 4,968.81 million in 2021; it is estimated to register a CAGR of 8.1% from 2021 to 2028.
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis - https://www.businessmarketinsights.com/sample/TIPRE00024558/?utm_source=OpenPR&utm_medium=10356
The "Europe high throughput screening market", based on product and service, is…
Global Neuropsychiatric Drugs Market– By Trends, Industry Competition Analysis …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Neuropsychiatric Drugs Market– By Trends, Industry Competition Analysis, Revenue and Forecast to 2030."
Request for Sample Pages: https://www.insightaceanalytic.com/report/global-neuropsychiatric-drugs-market-/1170
Neuropsychiatric disorders include a broad range of medical conditions that consist of both neurology and psychiatry. Disturbance in the function of the cerebral system leads to mental disorders. These disorders are majorly observed in children and adolescents. Numerous drugs are…
Global Neuropsychiatric Drugs Market Assessment 2020 – Key players such as Sag …
InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on “Global Neuropsychiatric Drugs Market Assessment – Revenue (US$ Mn) Forecast To 2028”
Request for Sample Pages: https://www.insightaceanalytic.com/report-details/global-neuropsychiatric-drugs-market-assessment/
According to the latest research by InsightAce Analytic, the global market for neuropsychiatric drugs is estimated to be valued at US$ XX million in 2020 and is expected to reach US$ XX million by 2028, with a remarkable CAGR of XX%…
Drug Addiction Market - Pipeline Review, H2 2020
Latest document on 'Drug Addiction - Pipeline Review, H2 2020' is added in HTF MI research reporsitory provides in-depth analysis, Competitive scenario, and future market trends and strategies. The regional analysis includes countries like USA, Germany, China, France, Japan, South Korea, UK, BeNeLux, Nordic Nations, Middle East & Africa and many other countries along with major players profiled. The Market has witnessed continuous growth in the past few years and…
Central Nervous System Drugs Market Along With Covid-19 Impact Analysis and Drug …
The latest market report on Central Nervous System Drugs Market 2019 offers an in-depth analysis of this business vertical involving key information concerning industry deliverables, predominantly market tendencies, market size, market share, present valuation, and profits estimations for the estimated period. The brief information regarding the industry also analyzes and elucidates the Central Nervous System Drugs Market growth rate in the forecast timeline, incited by certain catalysts.
The global Central Nervous…
